UK Introduces 'World-First' Law Enabling Point-Of-Care Manufacture of Personalised Medicines
Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), the new legislation allows personalised medicines to be prepared in small or individual batches right where patients are treated.
Cancer Treatments | 24/07/2025 | By Dineshwori
SMPA and NCI Collaborate to Expand Potential of Enzomenib in Precision Oncology
Enzomenib is an investigational, oral, small-molecule currently being clinically evaluated by SMPA in Phase 1/2 clinical trials for relapsed or refractory acute leukemia.
Cancer Treatments | 15/04/2025 | By Abha | 160
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy